PPARGC1A and osteoporosis: For example, PGC-1α and ERRα, which commonly influence body fat, visceral fat accumulation, and bone marrow adiposity in postmenopausal women, can be used as new therapeutic targets for bone loss and osteoporosis as well as abnormal lipid metabolism.